<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Els Van Valckenborgh</style></author><author><style face="normal" font="default" size="100%">E Boone</style></author><author><style face="normal" font="default" size="100%">A Camboni</style></author><author><style face="normal" font="default" size="100%">JP Defour</style></author><author><style face="normal" font="default" size="100%">B Denys</style></author><author><style face="normal" font="default" size="100%">H Devos</style></author><author><style face="normal" font="default" size="100%">L Dewispelaere</style></author><author><style face="normal" font="default" size="100%">Guy Froyen</style></author><author><style face="normal" font="default" size="100%">Aline Hébrant</style></author><author><style face="normal" font="default" size="100%">P Heimann</style></author><author><style face="normal" font="default" size="100%">P Hermans</style></author><author><style face="normal" font="default" size="100%">E Heylen</style></author><author><style face="normal" font="default" size="100%">K Jacobs</style></author><author><style face="normal" font="default" size="100%">F Lambert</style></author><author><style face="normal" font="default" size="100%">Marie Le Mercier</style></author><author><style face="normal" font="default" size="100%">Els Lierman</style></author><author><style face="normal" font="default" size="100%">H Louagie</style></author><author><style face="normal" font="default" size="100%">B Maes</style></author><author><style face="normal" font="default" size="100%">MB Maes</style></author><author><style face="normal" font="default" size="100%">G Martens</style></author><author><style face="normal" font="default" size="100%">L Michaux</style></author><author><style face="normal" font="default" size="100%">Friedel Nollet</style></author><author><style face="normal" font="default" size="100%">H A Poirel</style></author><author><style face="normal" font="default" size="100%">Gordana Raicevic</style></author><author><style face="normal" font="default" size="100%">P Saussoy</style></author><author><style face="normal" font="default" size="100%">T Tousseyn</style></author><author><style face="normal" font="default" size="100%">Marc Van den Bulcke</style></author><author><style face="normal" font="default" size="100%">P Vandenberghe</style></author><author><style face="normal" font="default" size="100%">Karl Vandepoele</style></author><author><style face="normal" font="default" size="100%">P Vannuffel</style></author><author><style face="normal" font="default" size="100%">T Venken</style></author><author><style face="normal" font="default" size="100%">K Vermeulen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Diagnostic testing in myeloid malignancies by next-generation sequencing: recommendations from the commission personalised medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Belgian Journal of Hematology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">249</style></number><volume><style face="normal" font="default" size="100%">10</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Molecular diagnostics have an increasing impact on diagnosis, risk stratification and targeted treatment in haemato-oncology. In the framework of a pilot study for the implementation of next-generation sequencing in the Belgian healthcare system, the Commission of Personalised Medicine was founded to give professional and evidence-based advice on the molecular analysis in haemato-oncology. This paper describes its recommendations for NGS analysis in myeloid malignancies. In addition, the minimally required set of genes that must be analysed is defined and algorithms for molecular workflow in myeloid malignancies are proposed.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><section><style face="normal" font="default" size="100%">241</style></section></record></records></xml>